0UNL.LSE Nektar Therapeutics

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-18.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0UNL.LSE undervalued?

Graham number

The Graham number of Nektar Therapeutics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nektar Therapeutics fundamental analysis

No fundamental analysis for Nektar Therapeutics yet.

Nektar Therapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; a…

Full company profile